Global Animal Growth Promoters And Performance Enhancers Market

Animal Medicine Market Definition

The animal medicine market consists of sales of veterinary medicines and related services by entities (organizations, sole traders and partnerships) that manufacture veterinary medicines used to treat animal diseases and/or to improve animals’ performance and health. The animal medicine industry includes establishments that manufacture veterinary pharmaceuticals such as veterinary vaccines, veterinary antibiotics, and other veterinary pharmaceuticals, and establishments that manufacture medical feed additives and nutritional feed additives.

The non-animal alternatives testing market consists of sales of non-animal alternatives testing products and services that do not involve the use of animals for tests to determine the safety standards for products. The non-animal alternatives testing market involves testing for drugs, cosmetic products using non- animal testing methods. Organs-on-chip, In-vitro test, In-silico test are some examples of techniques and methodologies used as an alternative to animal testing. The non-animal alternative testing market covered in this report is segmented by technology into cell culture technology, high throughput technology, molecular imaging, omics technology. It is also segmented by method into cellular assay, biochemical assay, in silico, ex-vivo and by end-user into pharmaceutical industry, cosmetics & household products, diagnostics, chemicals industry, food industry. The global non-animal alternatives testing market is expected to grow from $1.11 billion in 2020 to $1.23 billion in 2021 at a compound annual growth rate (CAGR) of 10.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The non-animal alternatives testing market is expected to reach $1.8 billion in 2025 at a CAGR of 10%. The support from the government and non-governmental organisations boosts the growth of the non-animal testing market. The government organisations enforces laws and regulations, raises funds to support the non-animal testing methods such as tests on human volunteers, advanced computer-modelling techniques and also funds studies with human volunteer. In order to support the non-animal testing, US Environmental Protection Agency (EPA), in 2019, awarded $4.25 million to the USA based universities including Johns Hopkins University, Vanderbilt University, Oregon State University, and the University of California to research for alternative tests replacing animals with non-animal alternatives and to make the test procedures less painful to the laboratory animals. Similar research programs to promote non-animal testing procedures are also initiated by countries such as Denmark, Brazil, Germany, Switzerland, Australia, China and Korea. The constant support from the government drives the growth of the non-animal testing market. Compulsory animal testing is required for the approval of sale of various products such as the pesticides, industrial chemicals, drugs, medical devices, vaccines, genetically modified foods, and some consumer products. Animal testing is still a mandatory practice in some countries due to their legal system where any special use products, non- routine tests, imported cosmetic requires animal testing. For instance, according to the UK's annual statistics of scientific procedures on living animals, in 2018, a total of 3.52 million experiments were completed on animals. According to Cruelty Free International, in 2018, in the UK almost 40 eye irritation tests, 10,275 acute lethal toxicity tests, and 638 pyrogenicity experiments were conducted on live rabbits. Cruelty Free International is an U.K based animal protection and advocacy group. The legal requirements in some countries for compulsory animal testing will hamper the growth of the market. The companies in the non-animal testing market are increasingly investing in technologies such as organs on the chip technology as an alternative to animal testing. Organs- on the- chip method contains human cells on a chip which mimics the structure and function of human organs and organs system instead of using of animal for the test. Following the trend, in 2018, Emulate was funded an amount of $36 million from its founder's fund and ALS Investment Fund, SciFi VC, GlassWall Syndicate Association to extended its biological capabilities to Liver-Chip, Intestine-Chip, Lung-Chip, and Brain-Chip, and to its human-relevant models of thrombosis and immune system modulation. ALS Investment Fund, SciFi VC and GlassWall Syndicate Association are venture capital and private equity firm that supports and finances biotech companies. In 2018, Thermo Fisher Scientific Inc., a USA based life sciences research company, acquired Advanced Bioprocessing business from Becton, Dickinson and Company for $477 million in cash. Through this acquistion Thermo Fisher Scientific Inc. aimed to expand its bioproduction portfolio by utilising the cell-culture media products of the Becton, Dickinson and Company. The Becton, Dickinson and Company is a USA based medical device company. Major players in the non-animal alternatives testing market are HµRel Corporation, Cyprotex, VITROCELL, SIMULAB, Bio-Rad Laboratories, GE Healthcare, SGS SA, BioIVT, Abbott Laboratoriesand Gentronix Limited. The regions covered in the non-animal alternatives testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-animal alternatives testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global non-animal alternatives testing market is segmented - 1) By Technology: Cell Culture Technology, High Throughput Technology, Molecular Imaging, Omics Technology 2) By Method: Cellular Assay, Biochemical Assay, In Silico, Ex-Vivo 3) By End-User: Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemicals Industry, Food Industry

Animal Testing Market Definition

The animal testing market consists of the total expenses incurred by end-use entities that use animals for testing their products. End-use entities include academic research institutions and various industries (such as pharmaceuticals, medical devices, chemicals & pesticides and cosmetics,) that conduct animal testing during product development. Pharmaceutical and medical device companies also use animal testing to understand basic disease mechanisms. End-use entities may also outsource these tests to clinical research organizations (CROs). The animal testing market covered in this report includes sales of animal testing services by CROs to end use industries. The market includes the costs of animal models and the costs of animal testing operations (such as animal maintenance and feed) during drug/ product testing. This market does not include animals caged in companies as stock and not used for testing, and animals used for breeding.

Non-Animal Alternative Testing Market Definition

The non-animal alternative testing market is the total expenses incurred by end-use entities that use alternative technologies instead of animals for testing their products. End-use entities include academic research institutions, and various industries (such as pharmaceuticals, medical devices, chemicals & pesticides and cosmetics) performing animal testing to conduct basic research, toxicology profiling, and others. The non-animal testing market covered in this report includes sales of non-animal testing services by CROs to end use industries. The market is inclusive of the costs of alternate technology tools and other operational costs involved in using these tools for various preclinical testing purposes.

The companion animal veterinary vaccines market consists of sales of companion animal vaccines by entities (organizations, sole traders and partnerships) that manufacture companion animal vaccines. Companion animal vaccines are substances that are used to stimulate the production of antibodies and provide immunity against one or several diseases in pets such as dogs, birds and cats. Only goods and services traded between entities or sold to end consumers are included. The global companion animal veterinary vaccines market is expected to grow from $2.599 billion in 2020 to $2.755 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $3.848 billion in 2025 at a CAGR of 9%. Increased pet ownership by Gen X and Gen Y adults contributed to the growth of the companion animal veterinary vaccines market during the historic period. According to the APPA, millennials, or Gen Y represents the largest segment of pet owners for all types of pets. More than 80% of Gen Y and Gen Z own a dog and 50% or less owns a cat as a pet. Multiple pet ownership is also on the rise in some parts of the world. In the USA, nearly 57% of all households owned pets in 2016. According to the 2019-2020 APPA National Pet Owners Survey, 67% of US households own pets, which is equal to 84.9 million homes. Pet owners are well aware of advanced facilities and are willing to spend a large amount of money on the health of their pets. Therefore, the rise in pet ownership aids in the growth of the companion animal veterinary vaccines market. The high cost of veterinary vaccines is expected to restrain the growth of the market. According to data from Harris Interactive, in 2015, in the USA, households with pets spent about $1,000 in pet care. There are around 70% of households in the USA who own a pet and only 39% have enough in their savings to cover high spending related to pet care. According to a report by PET IQ in 2019, in the USA, nearly 28% of households experienced barriers to veterinary care in the past two years. 80% of pet owners are unable to obtain preventative care due to financial constraints. There are several instances when it happens that the pet owners cannot afford expensive animal treatment and this factor restrained the growth of the companion animal veterinary vaccines market. Usually, the average cost of the rabies vaccine varies typically from about $1,200 to $6,500. Thus, the high costs for companion animal veterinary vaccines will restrain the growth of the market over the forecast period. Companies in the companion animal veterinary vaccine industry are increasingly collaborating and partnering with other players to drive product innovations. To succeed in the increasingly competitive veterinary market, companion animal veterinary vaccines companies are entering into new geographies and developing innovative products through sharing skills and expertise with other players. In June 2018, Merck & Co.’s subsidiary MSD Animal Health announced a strategic partnership with Vinovo B.V., a division of Viscon Hatchery Automation, the leading hatchery automation company, to provide a new standard in safe and effective in ovo vaccination to improve bird welfare and reduce vaccine reactions. In June 2017, Zoetis collaborated with a multidisciplinary team of public and private partners spanning animal and human health. In April 2019, Merck Animal Health, a US-based company that is involved in manufacturing, fabricating or processing of drugs for human or veterinary use, acquired Antelliq Corporation for about $2.4 billion. Through this acquisition, Merck Animal Health aims to implement animal health digital tracking, traceability and monitoring technology and complement the existing portfolio of vaccines and pharmaceuticals. Antelliq Corporation is an animal intelligence group that provides devices for animal identification, monitoring and traceability. The major players covered in the global companion animal veterinary vaccines market are Boehringer Ingelheim, Eli Lilly and Company (Elcano), Heska Co., Merck Animal Health, Virbac, Zoetis, ElancoCeva Sante Animal S.A., Bayer Healthcare, NEOGEN CORPORATION, ImmuCell Corporation, Intervet Inc. (Merck Animal Health). The countries covered in the global companion animal veterinary vaccines market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global companion animal veterinary vaccines market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global companion animal veterinary vaccines market is segmented - 1) By Product: Inactivated, Live Attenuated, Recombinant, Others 2) By Route Of Administration: Oral, Parenteral, Others 3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others

The veterinary healthcare market consists sales of goods and services by entities (organizations, sole traders and partnerships) associated with diagnosis, treatment and prevention of diseases in animals. This industry includes establishments that provide veterinary services, veterinary medical equipment producers and animal medicine producers.

The animal and pet food market consists of sales of animal and pet foods by entities (organizations, sole traders and partnerships) that produce food and feed for animals and pets from ingredients, such as grains, oilseed mill products, and meat products. The animal and pet food market is segmented into pet food and animal food. The global animal and pet food market is expected to grow from $305.86 billion in 2020 to $318.38 billion in 2021 at a compound annual growth rate (CAGR) of 4.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $406.35 billion in 2025 at a CAGR of 6%. Asia Pacific was the largest region in the global animal and pet food market, accounting for 33% of the market in 2020. North America was the second largest region accounting for 25% of the global market. Africa was the smallest region in the global animal and pet food market. The animal and pet food market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) predicts that the global GDP growth will be 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. Stable economic growth is expected to increase investments in the end user markets, thereby driving the market during forecast period. The outbreak of the Coronavirus disease (COVID-19) has acted as a massive restraint on the animal and pet food market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and spread globally including Western Europe, North America and Asia. Food and beverage manufacturers depend on supply of raw materials from domestic and international suppliers. As many governments restricted the movement of goods across countries and locally, manufacturers had to halt production due to lack of raw materials. Also, restrictions on trade of non-essential goods and fear of contamination through manufacturing facilities contributed to the decline. The outbreak is expected to continue to have a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the animal and pet food market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy. Pet food manufacturing companies are using automation technologies such as advanced production lines and software solutions to improve safety and operational efficiency. These technologies automate formulation, extrusion, batching, drying, coating and liquid delivery processes. This results in cost-effective processing and consistent product quality. For example, Champion Petfoods, a Canadian producer of pet food, has video monitored production lines, with cooking processes connected through Rockwell hardware and software systems. It also uses bulk bins and conveying systems, votator heat exchangers and advanced extrusion and drying systems. United Pet Group’s pet food manufacturing plant in St. Louis used FactoryTalk software from Rockwell Automation to reduce overtime by 10% and increase labor efficiency by 15%. Major companies in the market include Nestlé Purina; Mars Petcare Inc.; Big Heart Pet brands; Blue Buffalo; Hill's Pet Nutirion. The countries covered in the global animal and pet food market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global animal and pet food market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global animal and pet food market is segmented - 1) By Type: Pet Food, Animal Food 2) By Distribution Channel: Supermarkets/Hypermarkets, Convenience Stores, E-Commerce, Others 3) By Ingredients: Animal Derivatives, Plant Derivatives, Synthetic Subsegments Covered: Dog And Cat Food, Other Pet Food, Poultry Feed, Cattle Feed, Aquaculture Feed, Other Animal Food

Animal Hospitals and Veterinary Clinics Market Definition

The animal hospitals and veterinary clinics market consists of sales of veterinary services and related goods by animal hospitals and veterinary clinics. These entities (organizations, sole traders and partnerships) provide veterinary services to pets, farm animals and animals kept in zoos and wildlife parks. This industry includes animal hospitals and veterinary clinics that provide veterinary healthcare services such as consultation services, treatment, and curative medicines to animals. Healthcare is required in cases of disease or injury and for health maintenance and management of animals/livestock.